Why VitaSmart’s FDA nod could shift transplant strategies for extended-criteria grafts

Find out how Bridge to Life’s FDA-cleared VitaSmart system could reshape liver transplant workflows in 2026.

Find out how Bridge to Life’s FDA-cleared VitaSmart system could reshape liver transplant workflows in 2026.

LifeNet Health has announced the acquisition of Tissue Testing Technologies LLC (T3), a South Carolina–based biotechnology company specializing in advanced biopreservation. The deal expands LifeNet Health’s capabilities in organ and tissue preservation by integrating proprietary vitrification and warming technologies developed by Tissue Testing Technologies. The transaction is positioned to enhance clinical transplantation success rates, support […]